Skip to main content
main-content

01.12.2018 | Research | Ausgabe 1/2018 Open Access

Antimicrobial Resistance & Infection Control 1/2018

A systematic review of the epidemiology of carbapenem-resistant Enterobacteriaceae in the United States

Zeitschrift:
Antimicrobial Resistance & Infection Control > Ausgabe 1/2018
Autoren:
Daniel J. Livorsi, Margaret L. Chorazy, Marin L. Schweizer, Erin C. Balkenende, Amy E. Blevins, Rajeshwari Nair, Matthew H. Samore, Richard E. Nelson, Karim Khader, Eli N. Perencevich
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s13756-018-0346-9) contains supplementary material, which is available to authorized users.

Abstract

Background

Carbapenem-resistant Enterobacteriaceae (CRE) pose an urgent public health threat in the United States. An important step in planning and monitoring a national response to CRE is understanding its epidemiology and associated outcomes. We conducted a systematic literature review of studies that investigated incidence and outcomes of CRE infection in the US.

Methods

We performed searches in MEDLINE via Ovid, CDSR, DARE, CENTRAL, NHS EED, Scopus, and Web of Science for articles published from 1/1/2000 to 2/1/2016 about the incidence and outcomes of CRE at US sites.

Results

Five studies evaluated incidence, but many used differing definitions for cases. Across the entire US population, the reported incidence of CRE was 0.3–2.93 infections per 100,000 person-years. Infection rates were highest in long-term acute-care (LTAC) hospitals. There was insufficient data to assess trends in infection rates over time. Four studies evaluated outcomes. Mortality was higher in CRE patients in some but not all studies.

Conclusion

While the incidence of CRE infections in the United States remains low on a national level, the incidence is highest in LTACs. Studies assessing outcomes in CRE-infected patients are limited in number, small in size, and have reached conflicting results. Future research should measure a variety of clinical outcomes and adequately adjust for confounders to better assess the full burden of CRE.
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

Antimicrobial Resistance & Infection Control 1/2018 Zur Ausgabe